Clinical trials: Lobular Breast Carcinoma
Breast Cancer
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent breast cancer.
- Trial name
- NCT00245024
- Testing
- sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT02993159
- Testing
- Afimoxifene, Laboratory Biomarker Analysis, Tamoxifen Citrate
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University